Image Credit: CI Photos / Shutterstock.com Challenges associated with real-time data integration, analysis, and interpretation delay public health responses, particularly when HIV is considered.

Gilead's HIV drug lenacapavir earns FDA priority review after strong trial results, with the company planning to double U.S.

Between 2012 and 2022, new HIV infections nationwide decreased by 23% largely due to advanced medical treatments. However, a new analysis by KFF Health News and the Associated Press found that ...

Lenacapavir reduced HIV infections by 96% compared to ... sex with partners assigned male at birth. At interim analysis, the independent Data Monitoring Committee (DMC) confirmed that the PURPOSE ...

Background: Prevention programs often promote HIV testing as one possible strategy ... only 1 published report was found. Survey data from 7000 university students in Puerto Rico revealed that ...

It was based on an analysis of data from the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International Consortium (CATCH-IT). The team identified 390 patients with HIV and ...